Ellis M E, Weiss R B, Kuperminc M
Cancer Chemother Pharmacol. 1985;15(2):174-5. doi: 10.1007/BF00257532.
A patient is presented who developed nephrotoxicity after therapy with lomustine (CCNU) for astrocytoma of the brain. Only three other cases of lomustine nephrotoxicity have been reported, and all cases have been associated with cumulative drug doses of greater than 1,500 mg/m2. The clinical and pathologic features of lomustine nephrotoxicity are reviewed. It is recommended that cumulative doses of more than 1,200-1,4000 mg/m2 lomustine be avoided because of the risk of nephrotoxicity.
本文报告了1例脑星形细胞瘤患者在接受洛莫司汀(CCNU)治疗后发生肾毒性的病例。此前仅报道过另外3例洛莫司汀肾毒性病例,且所有病例均与累积药物剂量大于1500mg/m²有关。本文对洛莫司汀肾毒性的临床和病理特征进行了综述。鉴于存在肾毒性风险,建议避免使用累积剂量超过1200 - 1400mg/m²的洛莫司汀。